Evidence map›Paper›PMID 37108055›Full record

ArticleInternational journal of molecular sciences2023

Collateral Sensitivity to Fosfomycin of Tobramycin-Resistant Mutants of

Roberta Genova, Pablo Laborda, Trinidad Cuesta, José Luis Martínez, Fernando Sanz-García

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Roberta GenovaCentro Nacional de Biotecnología, CSIC, 28043 Madrid, Spain.
Pablo LabordaCentro Nacional de Biotecnología, CSIC, 28043 Madrid, Spain.
Trinidad CuestaCentro Nacional de Biotecnología, CSIC, 28043 Madrid, Spain.
José Luis MartínezCentro Nacional de Biotecnología, CSIC, 28043 Madrid, Spain.ORCID 0000-0001-8813-7607
Fernando Sanz-GarcíaCentro Nacional de Biotecnología, CSIC, 28043 Madrid, Spain.
Centro Nacional de Biotecnología · ESEstación Experimental del Zaidín · ESNovo Nordisk Foundation · DKUniversidad de Zaragoza · ES

Funding

MCIN/AEI/10.13039/501100011033 PID2020-113521RB-I00
6 · The paper itself

Abstract

Understanding the consequences in bacterial physiology of the acquisition of drug resistance is needed to identify and exploit the weaknesses derived from it. One of them is collateral sensitivity, a potentially exploitable phenotype that, unfortunately, is not always conserved among different isolates. The identification of robust, conserved collateral sensitivity patterns is then relevant for the translation of this knowledge into clinical practice. We have previously identified a robust fosfomycin collateral sensitivity pattern of

Indexed as

FosfomycinTobramycinAnti-Bacterial AgentsDrug Collateral SensitivityGenomicsMicrobial Sensitivity TestsPseudomonas aeruginosaAnti-Bacterial AgentsFosfomycinTobramycinantibiotic resistancebacterial evolutioncollateral sensitivityevolution contingencyfosfomycinPseudomonas aeruginosatobramycin

Identifiers

PMID37108055
PMCPMC10138353
OpenAlexW4362699257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.